ImmunityBio (IBRX) Stock Forecast: What Could Drive It in 2026
Last updated July 2026
Short answer
What is actually driving ImmunityBio (IBRX) right now is Anktiva revenue ramp: Net product revenue grew roughly 700% in full-year 2025 to about ~$113M, and Q1 2026 revenue rose about 168% year over year to roughly ~$44M. Revenue (FY2025) is ~$113M net product revenue. If that keeps playing out, the setup is favourable; the risk to it is iBRX carries the full risk profile of an unprofitable commercial-stage biotech. No one can predict where IBRX trades, and Walnut does not publish targets, so treat this as a scenario, not a price target or prediction.
What could drive ImmunityBio (IBRX) higher?
1. Anktiva revenue ramp
Net product revenue grew roughly 700% in full-year 2025 to about ~$113M, and Q1 2026 revenue rose about 168% year over year to roughly ~$44M. Continued physician uptake in BCG-unresponsive NMIBC is the core near-term growth engine. The base is still small, so percentage growth can stay high while absolute dollars remain modest.
2. Label and indication expansion
ImmunityBio is pursuing expansion into BCG-naive NMIBC, with a pivotal trial reported as fully enrolled and an sBLA submission targeted for 2026, plus early data in lung cancer. Each additional approved use widens the addressable population. These expansions are also the main justification for the current valuation, so timing and outcomes matter a great deal.
3. Global commercial partnerships
The company has signed distribution and approval arrangements spanning roughly 33 to 34 countries across multiple regulatory jurisdictions. International approvals can add revenue without ImmunityBio bearing the full commercial cost. Execution across many geographies and partners adds complexity and uncertainty.
4. Broader immunotherapy pipeline
Beyond Anktiva monotherapy combinations, ImmunityBio is exploring NK-cell therapy and other immunotherapy combinations across solid tumors. A wider pipeline offers optionality if additional programs advance. Most of these remain early and unproven, so they are potential upside rather than current value.
What could weigh on IBRX?
IBRX carries the full risk profile of an unprofitable commercial-stage biotech. It reported large net losses (a Q1 2026 net loss of roughly ~$633M versus about ~$130M a year earlier, inflated by non-cash items, with an adjusted net loss near ~$86M) and burns roughly ~$75M of operating cash per quarter, which repeatedly requires financing that can dilute existing shareholders. Its market value (about ~$8.7B) is very large relative to trailing revenue (~$113M), so any slowdown in adoption, a negative regulatory decision, competitive pressure, or a difficult capital raise could move the stock sharply. Single-drug concentration and dependence on continued Anktiva execution compound these risks.
Where IBRX trades today
A forecast starts from where the stock actually is. These are IBRX's current figures, not a projection: the drivers and risks above are what would move them.
Snapshot for IBRX as of July 2026, sourced from Yahoo Finance and may be delayed. Valuation figures move with price and earnings; verify the current numbers with your broker before deciding.
How to think about a IBRX forecast
Rather than chasing a price target, it tends to help to weigh the drivers above against the risks, decide how long you are willing to hold, and size the position so a wrong call is survivable. A “forecast” is really a probability-weighted view of those drivers playing out, not a number.
For the full picture, see the IBRX guide and whether IBRX is a buy. In Walnut you can pressure-test the thesis against your real portfolio.
The bottom line on the IBRX outlook
The bottom line: what is driving ImmunityBio (IBRX) is Anktiva revenue ramp, with revenue (fy2025) at ~$113M net product revenue. If that keeps playing out the setup is favourable; the risk is iBRX carries the full risk profile of an unprofitable commercial-stage biotech. No one can predict the price, so treat any IBRX forecast as a scenario, not a target or prediction, and decide from your own thesis and time horizon. Walnut is not an investment adviser.
Build a basket around IBRX with Walnut
Use ImmunityBio as one constituent in a thematic basket Walnut's AI helps you assemble. Describe a thesis you believe in, the AI proposes the holdings and weights, and you approve before any broker order.
FAQ
What is the forecast for ImmunityBio (IBRX)?
+
No one can reliably predict where IBRX will trade, and Walnut does not publish price targets. What is more useful is the setup: the drivers that could push ImmunityBio higher and the risks that could weigh on it. This page lays out both so you can form your own view. Not a recommendation.
What could drive IBRX higher?
+
The main growth drivers are Anktiva revenue ramp; Label and indication expansion; Global commercial partnerships. Whether they play out is the real question, not a guaranteed path.
What are the risks to IBRX?
+
IBRX carries the full risk profile of an unprofitable commercial-stage biotech. It reported large net losses (a Q1 2026 net loss of roughly ~$633M versus about ~$130M a year earlier, inflated by non-cash items, with an adjusted net loss near ~$86M) and burns roughly ~$75M of operating cash per quarter, which repeatedly requires financing that can dilute existing shareholders. Its market value (about ~$8.7B) is very large relative to trailing revenue (~$113M), so any slowdown in adoption, a negative regulatory decision, competitive pressure, or a difficult capital raise could move the stock sharply. Single-drug concentration and dependence on continued Anktiva execution compound these risks.
Will IBRX stock go up in 2026?
+
Nobody knows, and anyone who says they do is guessing. ImmunityBio's direction depends on whether the drivers above outweigh the risks, plus the broader market. Focus on the thesis and your time horizon rather than a single-year call.
Is IBRX a buy?
+
That depends on your thesis, time horizon, and what you already own, not on a forecast. See the IBRX "is it a buy?" page for a framework. Walnut is not an investment adviser.
How fast is Anktiva revenue growing?
+
Very fast off a small base. Full-year 2025 net product revenue rose about 700% to roughly ~$113M, and Q1 2026 revenue grew about 168% year over year to roughly ~$44M. High percentage growth reflects the early stage of the launch.
Walnut is informational, not investment advice. This page describes drivers and risks; it is not a price forecast, target, or recommendation. Markets are uncertain and past performance does not predict future results.